Navigation Links
GeoVax Secures $10 Million Financing Commitment
Date:5/12/2008

ATLANTA, May 12 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta- based HIV/AIDS vaccine development company, announced today that it has entered into a $10 million common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional investor.

The Company may sell up to $10 million of its common stock to Fusion Capital from time to time over a 25-month period after the Securities and Exchange Commission has declared effective a registration statement related to the transaction. GeoVax will use the proceeds to further its developmental HIV/AIDS vaccine, expected to enter Phase 2 human clinical trials later this year.

Under the agreement, the Company has the right to sell shares of its common stock to Fusion Capital from time to time in amounts between $80,000 and $1 million, depending on certain conditions, up to $10 million in the aggregate. The purchase price of the shares will be based on the prevailing market prices of the Company's shares at the time of sales without any fixed discount, and the Company will control the timing and amount of any sales of shares to Fusion Capital. There are no negative covenants, restrictions on future financings, penalties or liquidated damages in the agreement. A more detailed description of the agreement is set forth in the Company's Current Report on Form 8-K filed today with the SEC, which should be reviewed carefully with this press release.

"We are very pleased to establish this funding relationship with Fusion Capital, a well-respected institutional investor with a strong track record of investments in the technology and healthcare sectors," Robert T. McNally, GeoVax's President and CEO, said.

Dr. McNally continued, "This agreement will help us continue to move forward with our AIDS vaccine development efforts. Combined with the five- year, $15 million federal grant GeoVax was awarded last year and the direct support we expect to
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
2. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
3. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
4. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
7. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
8. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
9. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
10. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
11. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...v.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: AB...carebloodanalysissystems,announcedtodaythatClintSe...tatthe21stAnnualPiperJaffrayHealthCareConferenceon...willbeheldattheNewYorkPalaceHotelinNewYorkCity. ,...sandmarketsportablebloodanalysissystemsforuseinany...
(Date:11/25/2009)....25/PRNewswire/--CempraPharmaceuticalsInc.todayann...ecutiveofficer,willpresentatthePiperJaffray21stAnn...9,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernande...bioticclinicalprogramsforthetreatmentofdrug-resist...aceuticals ,, Foundedin2006,CempraPharmaceutic...
(Date:11/25/2009)...SYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareInte...vatorandprovideroflessinvasive,miniaturizedcircula...ofadvancedheartfailure,todayannouncedthatitissched...erJaffrayHealthCareConferenceat8:00amESTonWednesda...orkPalaceHotel,December1-2. ,, Alivewebcastofth...
Breaking Medicine Technology:Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 1Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 2Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 3SPIRIT IV trial shows everolimus stent sets new standard for event free survival 58174 1SPIRIT IV trial shows everolimus stent sets new standard for event free survival 58174 2Depression and anxiety disorders of adolescents are not the same thing 10069 1
...of research reflects depth and breadth of, collab...w treatments for diverse fo...act of Zometa(R), the leading IV, bisphosphonate, ...t cancer, - Four oral sessions to feature RAD001,...OR, including first results of RECORD-1 study in r...
...ns demonstrated in Blacks, Hispanics/Latinos, Peop...duals, PARSIPPANY, N.J., May 15 Daiichi Sankyo, ...erican Society of,Hypertension,s Twenty- Third Ann...emonstrated that the powerful combination drug AZO... and effectively helped,patients across several ma...
Other Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7
(Date:11/25/2009)...,Nov.25/PRNewswire-USNewswire/--TheBlackAIDSInstit...executiveleadershipfor2010. ,, ThenewBoardMembe...publicpolicy,law,finance,governmenthealthprograms,...comesfromawiderangeofpersonalbackgroundsincludingb...thHIVthemselves,andrepresentingmultipleagegroups. ...
(Date:11/25/2009)... found evidence of a statistically significant sur...ts whose estrogen receptor (ER)-positive tumors ha...erine-118 (ER-alpha S118-P), according to a brief ... Journal of the National Cancer Institute . , Ap... to tamoxifen. Preclinical studies have shown that...
(Date:11/25/2009)... used to fight rheumatoid arthritis, could help ne... WEDNESDAY, Nov. 25 (HealthDay News) -- A drug com...umatoid arthritis now also shows some promise in h...es. , The drug, rituximab (Rituxan), helped pat...en though the disease had destroyed some of their ...
(Date:11/25/2009)...ote, CDC sees few signs of trouble with the H1N1 v...ay News) -- The ongoing H1N1 swine flu pandemic ma...s among younger patients, a U.S. health official s...serious pneumococcal infections around the country...ter for Immunization and Respiratory Diseases at t...
(Date:11/25/2009)... -- A cancer vaccine carried into the body on a ca...e first to successfully eliminate tumors in mammal...ence Translational Medicine . , The new approach...arvard University, uses plastic disks impregnated ...he skin to reprogram the mammalian immune system t...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2
...ost common surgical procedures performed worldwide... called computed tomography can be used to predict...to a new study. Researchers examined 105 patie...ity of acute appendicitis. The study showed CT, wh...
...ffecting more than 2 million people worldwide and ...cuits // of the brain that result in seizures. Mor...e-free by taking medications. Researchers say a...common form of the disorder. Typically, about 80 p...
...ting active can help elderly patients who have tro...// 12 healthy adults between the ages of 67 and 86...m consisted of 30 minutes of exercise followed by ...ticipants first taking part in one of the time per...
...n relief and improves function for people with ost... complement to Normal care. This study was funded ...native Medicine (NCCAM) and the National Institute...ngest and largest randomized, controlled phase III...
... number of countries where iodine deficiency is a ...O Study on a new global report on iodine status.//...as worked well. The number of countries where iodi...lopment of people worldwide, particularly preschoo...
... that for those suffering form asthma, the key to ...earchers conducted a study to look at the connecti...rs. It was found that the higher incidence of asth...l for life on earth because it absorbs the destruc...
Other Medicine News:Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 2Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 3Health News:WHO hopes to wipe away Iodine deficiency diseases by 2005 2
Max-Rom Acetabular Liners
Cofield 2 Total Shoulder System
Integrated Shoulder System
...index. A/P and lateral fins with holes for suture ...al hole, humeral / glenoid diametral curvature mis...ugh textured proximal surface to provide enhanced ...esistance in cement, six stem sizes, fifteen head ...
Medicine Products: